应用嵌合抗原受体修饰T细胞治疗乳腺癌研究进展

Chimeric antigen receptor engineered T-cells in the treatment of breast cancer

嵌合抗原受体修饰T细胞在治疗血液系统恶性肿瘤中取得了良好治疗效果。嵌合抗原受体修饰T细胞是通过基因修饰方法获得针对肿瘤细胞表面特定抗原的特异性T细胞。嵌合抗原受体具有赋予T细胞更强的靶向性并能打破宿主免疫耐受状态等理论优势,但由于乳腺癌等实体肿瘤的脱靶效应、免疫细胞不易进入瘤体内部等因素,该应用尚处于临床前实验阶段。本文就嵌合抗原受体修饰T细胞在乳腺癌治疗中应用的研究进展作一综述。

In recent years,adoptive transfer of chimeric antigen receptor(CAR)engineered T-cells has demonstrated robust and durable clinical efficacy in patients with hematology malignancy.CAR engineered T-cells are the specific T-cells for tumor surface specific antigen obtained by gene modification.CAR has several technical advantages,such as endowing great targeting ability to T-cells,breaking the state of immune tolerance and so on.Because of existed off-target effects of solid tumors such as breast cancer and the poor penetration of immune cells into the breast tumor tissue,this application is still in preclinical trials.This paper reviews the research progress of the application of CAR engineered T-cells in the treatment of breast cancer.